Department of Infectious Diseases, Hunan Provincial People's Hospital (The First-affiliated Hospital of Hunan Normal University), Changsha, Hunan, China.
Institute of Emergency Medicine, Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial People's Hospital (The First-affiliated Hospital of Hunan Normal University), Changsha, Hunan, China.
BMC Infect Dis. 2021 Aug 3;21(1):737. doi: 10.1186/s12879-021-06447-3.
The serum surfactant protein D (SP-D) level is suggested to be a useful biomarker for acute lung injuries and acute respiratory distress syndrome. Whether the serum SP-D level could identify the severity of coronavirus disease 2019 (COVID-19) in the early stage has not been elucidated.
We performed an observational study on 39 laboratory-confirmed COVID-19 patients from The Fourth People's Hospital of Yiyang, Hunan, China. Receiver operating characteristic (ROC) curve analysis, correlation analysis, and multivariate logistic regression model analysis were performed.
In the acute phase, the serum levels of SP-D were elevated significantly in severe COVID-19 patients than in mild cases (mean value ± standard deviation (SD), 449.7 ± 125.8 vs 245.9 ± 90.0 ng/mL, P<0.001), while the serum levels of SP-D in the recovery period were decreased dramatically than that in the acute phase (mean value ± SD, 129.5 ± 51.7 vs 292.9 ± 130.7 ng/ml, P<0.001), and so were for the stratified patients. The chest CT imaging scores were considerably higher in the severe group compared with those in the mild group (median value, 10.0 vs 9.0, P = 0.011), while markedly lower in the recovery period than those in the acute phase (median value, 2.0 vs 9.0, P<0.001), and so were for the stratified patients. ROC curve analysis revealed that areas under the curve of lymphocyte counts (LYM), C-reaction protein (CRP), erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), and SP-D for severe COVID-19 were 0.719, 0.833, 0.817, 0.837, and 0.922, respectively. Correlation analysis showed that the SP-D levels were negatively correlated with LYM (r = - 0.320, P = 0.047), while positively correlated with CRP (r = 0.658, P<0.001), IL-6 (r = 0.471, P = 0.002), the duration of nucleic acid of throat swab turning negative (r = 0.668, P<0.001), chest CT imaging score on admission (r = 0.695, P<0.001) and length of stay (r = 0.420, P = 0.008). Multivariate logistic regression model analysis showed that age (P = 0.041, OR = 1.093) and SP-D (P = 0.008, OR = 1.018) were risk factors for severe COVID-19.
Elevated serum SP-D level was a potential biomarker for the severity of COVID-19; this may be useful in identifying patients whose condition worsens at an early stage.
血清表面活性剂蛋白 D(SP-D)水平被认为是急性肺损伤和急性呼吸窘迫综合征的有用生物标志物。血清 SP-D 水平是否能在早期识别 2019 年冠状病毒病(COVID-19)的严重程度尚未阐明。
我们对来自中国湖南省益阳市第四人民医院的 39 例实验室确诊的 COVID-19 患者进行了观察性研究。进行了接收者操作特征(ROC)曲线分析、相关性分析和多变量逻辑回归模型分析。
在急性期,重症 COVID-19 患者的血清 SP-D 水平明显高于轻症患者(平均值±标准差,449.7±125.8 vs 245.9±90.0ng/ml,P<0.001),而恢复期的血清 SP-D 水平则明显下降与急性期(平均值±SD,129.5±51.7 vs 292.9±130.7ng/ml,P<0.001),分层患者也是如此。重症组的胸部 CT 影像学评分明显高于轻症组(中位数,10.0 vs 9.0,P=0.011),而在恢复期明显低于急性期(中位数,2.0 vs 9.0,P<0.001),分层患者也是如此。ROC 曲线分析显示,淋巴细胞计数(LYM)、C 反应蛋白(CRP)、红细胞沉降率(ESR)、白细胞介素-6(IL-6)和 SP-D 对重症 COVID-19 的曲线下面积分别为 0.719、0.833、0.817、0.837 和 0.922。相关性分析显示,SP-D 水平与 LYM 呈负相关(r=-0.320,P=0.047),与 CRP 呈正相关(r=0.658,P<0.001),与 IL-6 呈正相关(r=0.471,P=0.002),与咽拭子核酸转阴持续时间(r=0.668,P<0.001)、入院时胸部 CT 影像学评分(r=0.695,P<0.001)和住院时间(r=0.420,P=0.008)呈正相关。多变量逻辑回归模型分析显示,年龄(P=0.041,OR=1.093)和 SP-D(P=0.008,OR=1.018)是 COVID-19 重症的危险因素。
血清 SP-D 水平升高是 COVID-19 严重程度的潜在生物标志物;这可能有助于在早期识别病情恶化的患者。